PARP-1/HDAC-IN-1 

PARP-1/HDAC-IN-1 is a PARP-1/HDAC6 dual targeting inhibitor with IC₅₀s of 68.90 nM and 510 nM, respectively. PARP-1/HDAC-IN-1 displays remarkable anticancer, anti-migration and anti-angiogenesis activities^[1].

PARP-1/HDAC-IN-1 (Compound 1–8-6) possesses potent inhibitory activity against MDA-MB-436, ES-2, DU145, A549, HCC1937, and Capan-1 cells with IC₅₀ values of 0.35 μM, 1.16 μM, 3.38 μM, 5.67 μM, 2.85 μM, and 4.53 μM, respectively^[1].
PARP-1/HDAC-IN-1 (Compound 1–8-6; 0.3-10 μM) is able to heighten expression level of acetylated α-tubulin with marginal effects to acetylated histones H3 and H4^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

402.40

C₂₂H₁₈N₄O₄

3032621-10-3

NC(C1=CC=CC2=CN(N=C21)C3=CC=C(C=C3)OCC4=CC=C(C=C4)C(NO)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ziwei Chi, et al. Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors. Bioorg Med Chem Lett. 2022 Sep 1;71:128821.  [Content Brief]